Skip to main content

Alnylam shares surge 40% on drug results that may herald a new type of medicine

Many companies backed away from the gene silencing technique when big investments in the field didn’t pan out — but not Alnylam.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.